Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study

Hussain SA, Marouf BH, Ali ZS, Ahmmad RS · Clinical Interventions in Aging

Reported near-abolition of symptoms with the resveratrol add-on: total WOMAC (0-96) fell from 59.6 to 8.1 by day 90, while the meloxicam-plus-placebo arm barely moved (63.7 to 56). Liver and kidney markers and blood counts stayed normal, so 500 mg/day was well tolerated.

Population

Adults 45-75 with mild-to-moderate knee osteoarthritis (WOMAC >50/96 at baseline), Sulaimani, Iraq

Intervention

Resveratrol 500 mg once daily for 90 days, added to meloxicam 15 mg/day in both arms

Comparator

Placebo capsule (both arms continued meloxicam)

Limitations

The between-group effect dwarfs anything recorded for any osteoarthritis intervention, including NSAIDs themselves — the placebo-plus-meloxicam arm's near-total lack of improvement over 90 days is itself unusual. Single city (described as multi-center across its facilities), university-funded PhD project, completer-based analysis (50 vs 42 analyzed of 55 randomized per arm), baseline gender imbalance. Full text read; the numbers above are from its Table 4.